According to the Medicine Intelligence Data Investment Pattern Database, VFLO Medical, a peripheral vascular innovation medical device company, recently announced the completion of a Series B financing with a total amount of $80 million (approximately RMB 581 million). The financing was jointly participated by well-known investment institutions such as Tonghe Yucheng and its US dollar fund 120 Capital, a large family office, Hefei Production Investment, Hefei High tech Investment, and USTC Silicon Valley.

It is reported that the funds raised in this round will be used to support the clinical and promotion of innovative pipelines in the peripheral intervention field developed by Jitong Medical through multiple collaborations and self research. The aim is to meet the huge clinical demand in China's peripheral vascular field and bring more cutting-edge solutions for the treatment of peripheral vascular diseases.

Founded in 2021, Yitong Medical is jointly incubated by Tonghe Yucheng and 120 Capital. Its team is composed of well-known and experienced industry professionals, aiming to create a leading medical device platform that focuses on providing innovative vascular therapies for Chinese patients.

At the same time as announcing the completion of Series B financing, Jitong Medical has also reached a strategic partnership with Inari Medical (hereinafter referred to as Inari), obtaining the distribution rights for a series of innovative medical device products under Inari, including ClotTriever and FlowTriever, in Greater China, as well as the right to use Inari's technology for localized production and sales in Greater China.

Inari was founded in 2011 and is an innovative medical device company that focuses on developing products to treat venous disease patients and change their lives. Inari's two innovative products, ClotTriever and FlowTriever, are innovative minimally invasive mechanical thrombectomy platforms.

ClotTriever
ClotTriever is an innovative mechanical thrombectomy device developed specifically for deep vein thrombosis, which was approved for market by the FDA in February 2017. There are three models of this product, namely: ClotTriever catheter, which can collect and remove thrombi from blood vessels ranging from 6-16mm (including thrombi on the vessel wall); ClotTriever BOLD catheter adopts shortened collection stent and HyperClearTM technology to provide a faster operating room for DVT for deep vein thrombectomy; The ClotTriever XL catheter is the largest model in the ClotTriever series, designed specifically for effectively removing thrombi in the vena cava.

FlowTriever
FlowTriever is the world's first mechanical thrombectomy system for the treatment of pulmonary embolism, approved by the FDA in 2015, aimed at rapidly clearing thrombi and immediately improving symptoms in patients with acute pulmonary embolism. FlowTriever consists of two core components: the Triever suction duct and FlowTriever duct.

The Trieve suction catheter is a catheter with a large lumen diameter, high traceability, and can be used in conjunction with large caliber syringes to quickly aspirate large amounts of blood clots while reducing blood loss. The FlowTriever catheter is a catheter with three self expanding nickel titanium alloy mesh discs, available in four sizes, designed to lyse thrombi and deliver them to Triever20.

It is worth mentioning that both ClotTriever and FlowTriever products have entered the special review process for innovative medical devices.

Pulmonary embolism (PE) refers to a pathological and physiological syndrome of pulmonary circulation disorders caused by endogenous or exogenous emboli blocking the pulmonary arteries. It is a dangerous and severe cardiovascular disease in clinical practice, second only to acute myocardial infarction and stroke, and has become a common and frequent cardiovascular disease in China. It has the characteristics of "high missed diagnosis rate, high disability rate, and high mortality rate".

At present, a pulmonary embolism interventional device has been launched in China. In May 2024, Tendvia independently developed by Tengfu Medical ® The pulmonary artery thrombectomy stent system has been approved for market by the National Medical Products Administration (NMPA). As the first specialized interventional device for acute pulmonary embolism in China, it fills the gap in the treatment of pulmonary embolism with pulmonary artery thrombectomy stents.

Tendvia ® It consists of a pulmonary artery thrombectomy stent and a thrombus aspiration catheter, equipped with a thrombectomy stent, negative pressure aspiration, and synchronous mechanical thrombectomy; The unique thrombectomy stent basket structure effectively acts on various types of thrombi; Large caliber design, powerful suction; Multi segment structure design of the pipe body, balanced pushing and flexibility; The product features simple surgical operation and quick opening of blood vessels.

Therefore, the launch of ClotTriever and FlowTriever products will face Tendvia, who will be one step ahead of them ® This formidable opponent. However, Zhitong Medical is also confident in its cooperation with Inari. The management team of Zhitong Medical stated, "The company's team has been deeply involved in the peripheral vascular and cardiovascular intervention industry in China for many years, and has rich industry resources and experience. This strategic cooperation with Inari combines globally leading innovative products, excellent clinical trial data and real-world experience, as well as the professional teams of both parties. In the future, Zhitong will continue to provide high-quality solutions for peripheral vascular disease intervention treatment for Chinese doctors and patients through product introduction and independent research and development dual core drive

Source:
https://news.yaozh.com/archive/44653.html?u_atoken=2ee3c876058555ca3e674478a38eed57&u_asig=1a0c399817337996490137169e004c